Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.
Normanno N, Rachiglio AM, Lambiase M, Martinelli E, Fenizia F, Esposito C, Roma C, Troiani T, Rizzi D, Tatangelo F, Botti G, Maiello E, Colucci G, Ciardiello F; CAPRI-GOIM investigators.
Normanno N, et al.
Ann Oncol. 2015 Aug;26(8):1710-4. doi: 10.1093/annonc/mdv176. Epub 2015 Apr 7.
Ann Oncol. 2015.
PMID: 25851630
Free article.
Clinical Trial.